Holen Sie sich die Stockscreener-App
3.565
4.17%
-0.155
Handel nachbörslich:
3.57
0.005
+0.14%
Schlusskurs vom Vortag:
$3.72
Offen:
$3.72
24-Stunden-Volumen:
5,353
Relative Volume:
1.85
Marktkapitalisierung:
$143.94M
Einnahmen:
$7.80M
Nettoeinkommen (Verlust:
$-69.02M
KGV:
-1.6649
EPS:
-2.1413
Netto-Cashflow:
$-66.61M
1W Leistung:
-0.98%
1M Leistung:
-2.33%
6M Leistung:
-23.82%
1J Leistung:
-39.70%
1-Tages-Spanne:
$3.54
$3.86
1-Wochen-Bereich:
$3.54
$3.91
52-Wochen-Spanne:
$3.36
$7.60
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Firmenname
Molecular Partners Ag Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MOLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.565 | 142.09M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-12 | Fortgesetzt | SVB Leerink | Outperform |
Alle ansehen
Molecular Partners Ag Adr Aktie (MOLN) Neueste Nachrichten
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 - GlobeNewswire Inc.
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Cuts 40 Jobs, Extends Cash Reach to 2028 - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Can Contango ORE, Inc. (CTGO) Climb 163.28% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Musk's DOGE Exit Rumors & Weak Q1 Deliveries: How to Play Tesla Now - Yahoo Finance
Why Tractor Supply (TSCO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com India
Molecular Partners reports 2024 annual results - Investing.com India
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 - Novartis
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 - Novartis
Conference Calls and Individual Investors - MarketBeat
RocheDoing now what patients need next - Roche
Finanzdaten der Molecular Partners Ag Adr-Aktie (MOLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):